- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03572647
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
November 1, 2022 updated by: Azidus Brasil
Randomized Clinical Study for Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax, Marketed by the Blausiegel Laboratory, Compared to Drug Eprex, Produced by Janssen-Cilag Laboratory, in Healthy Subjects.
The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells.
This is a pharmacokinetics and pharmacodynamics study, in which each subject will receive the investigational product in different periods, as randomisation (Teste or Comparator).
The evaluation of the profile included serum dosage of medications and reticulocyte count in peripheral blood.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This a prospective randomized and crossover study for evaluation of pharmacokinetics and pharmacodynamics of two epoetins formulations.
The subjects will receive in each confinement period 4000 IU one of the investigational product subcutaneously, according to randomisation, separated by a washout period of 4 weeks.
The evaluation of the profile between products included serum dosage of medications and reticulocyte count in peripheral blood.
Safety evaluation data will include report od all adverse events (including type, frequency, intensity, seriousness, severity and action taken related to the investigational product study).
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13270000
- LAL Clínica Pesquisa e Desenvolvimento Ltda.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Confirm the voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;
- Being male, aged between 20 and 55 years, clinically healthy;
- BMI between 18 and 25;
- Results of examination of hemoglobin between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;
- Results of VCM, HBMC, platelets and leukocytes within the normal range:
VCM = Between 82 to 98. Among the HBMC = 26 to 34. Among the platelets = 150,000 to 400,000 units per mL. Among the WBC = 3,500 to 10,500 units per mL and without cellular atypia.
- Serum ferritin = Male between 36 to 262 mcg / L and women between 24 to 155 mcg / L;
- Reticulocyte count in peripheral blood ≤ 3%;
- Serum erythropoietin less than 30 mIU / mL.
Exclusion Criteria:
- Participation in clinical trials in the 12 months preceding the survey;
- Presence of iron deficiency anemia;
- Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
- Acute disease in the period of 07 days prior to inclusion;
- Chronic administration of medication to determine, such as high blood pressure;
- Hormone therapy in the period of 02 months prior to inclusion;
- Administration of any drug in the 02 weeks prior to inclusion;
- A history of autoimmune anemia or hereditary;
- research subjects with a history of chronic bleeding;
- research subjects with a history of acute bleeding in the last 30 days;
- History of sensitivity to biological products derived from mammals, albumin, or any component of the formulation;
- History of or current use at least 12 months of tobacco;
- Current or previous history (less than 12 months) of illicit drug use;
- previous therapy with erythropoietin;
- albumin below 3.5 g / dl or greater than 4.8 g / dL;
- Signs or clinical history of bone marrow aplasia;
- History of liver disease and clinical or laboratory;
- History of renal disease and clinical or laboratory.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Test ERITROMAX
Blausiegel Industria e Comercio Ltda.
Recombinant Human Erythropoietin (ERITROMAX)
|
The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Other Names:
|
ACTIVE_COMPARATOR: EPREX
Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
|
The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic - rHuEPO concentration.
Time Frame: Before administration (Time 0 hour) and after time 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 11 hours, 12 hours, 13 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours administration.
|
Will evaluated through the plasma rHuEPO dosage before and after drug administration.
|
Before administration (Time 0 hour) and after time 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 11 hours, 12 hours, 13 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours administration.
|
Pharmacodynamics - Absolute Reticulocyte Count.
Time Frame: Before administration (Time 0 hour) and after Time 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, 240 hours and 576 hours administration.
|
Will evaluated through the absolute reticulocyte count at total blood.
|
Before administration (Time 0 hour) and after Time 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, 240 hours and 576 hours administration.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexandre Frederico, PI, LAL Clínica Pesquisa e Desenvolvimento Ltda
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (ACTUAL)
November 1, 2012
Study Completion (ACTUAL)
May 1, 2013
Study Registration Dates
First Submitted
November 3, 2011
First Submitted That Met QC Criteria
June 19, 2018
First Posted (ACTUAL)
June 28, 2018
Study Record Updates
Last Update Posted (ACTUAL)
November 3, 2022
Last Update Submitted That Met QC Criteria
November 1, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPOBLA0711I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data will become public.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency, Chronic
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
University of PennsylvaniaTeleflex; Arrow InternationalCompletedRenal Failure Chronic Requiring Hemodialysis | Chronic Renal InsufficiencyUnited States
-
Hospices Civils de LyonCompletedChronic Renal Insufficiency | Cardiac TransplantationFrance
-
CHU de ReimsUnknownChronic Renal InsufficiencyFrance
-
Southern Medical University, ChinaTerminatedChronic Kidney Failure
-
Centre Hospitalier Universitaire de NiceTerminatedAged | Chronic Renal Insufficiency | Chronic Kidney FailureFrance
-
Azienda Sanitaria ASL Avellino 2UnknownChronic Renal InsufficiencyItaly
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
Clinical Trials on Eritromax
-
Azidus BrasilUnknown
-
Azidus BrasilUnknown